From the Prometic report on the company’s second quarter 2015 highlights and financial results:
“With our cash position combined with proceeds generated from our commercial activities, we are well positioned to execute on our development plans for our plasma-derived and small-molecule therapeutics”, said Mr. Bruce Pritchard, Chief Operating and Chief Financial Officer of ProMetic Life Sciences Inc.
From the business highlights:
- During the second quarter of 2015, ProMetic selected C1 Esterase Inhibitor (“C1-INH”) as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE, a rare genetic disorder in which C1-INH is lacking;